All posts by admin

Appellation program, cooperatives might give small California cannabis farmers a boost

Appellation program, cooperatives might give small California cannabis farmers a boost

Small marijuana farmers in California who’ve struggled in recent years – either to launch their own brands, expand their businesses or survive the transition to the new legal market – might have a brighter future, thanks in part to various programs and ventures now in the works.

Some of those include:

An appellations program run by the state.

Farming cooperatives designed to bolster craft growers.

Co-branding ventures between distributors and farmers.

The likelihood of new banking access, business loans and capital to allow for expansion and brand development.

“Brand building is massive. I believe brand value will far exceed our product value,” said Nik Erickson, the owner of Full Moon Farms in Humboldt County. (Humboldt, Mendocino and Trinity are the three counties that comprise the Emerald Triangle.)

Read More

Published at Wed, 25 Nov 2020 16:12:35 +0000

Georgia Now Accepting Cannabis Cultivation Applications

Georgia Now Accepting Cannabis Cultivation Applications

New Jersey, despite its left-leaning politics and proximity to one of the world’s largest urban centers, has lagged behind in cannabis. As the 11th-largest state in the country by population, New Jersey has fewer than 14 medical cannabis dispensaries serving close to 100,000 patients. Possession of marijuana was just decriminalized there last year.

Garden State cannabis also has a racial equity problem. Black residents are between two and three times more likely to be arrested for possession of marijuana despite relatively equal rates of use across races. In some counties, Black people are arrested over 30 times more frequently for cannabis, according to a 2020 report from the ACLU of New Jersey.

New Jersey passed legalization in November’s election by a landslide—more than two in three voters approved. But state cannabis advocates are now calling out serious shortcomings in the proposed A-21/S-21 bill, saying it doesn’t do enough to address the harsh repercussions of the drug war and will keep minority and disadvantaged small businesses from participating in the upcoming industry. 

What’s in (and not in) A-21/S-21?

“[The bill] has been introduced as the most progressive cannabis legislation in the country yet it falls short of substantive social equity provisions seen in other states,” said Jessica Gonzalez, General Counsel for Minorities for Medical Marijuana (M4MM), in an email to Cannabis Business Times and Cannabis Dispensary.

“The bill is riddled with vague language and predatory programs aimed at minority communities while increasing the barriers to entry,” said Gonzalez. Specifically, she identified five points where it falls short:

  • Lack of allocation of cannabis tax revenue to communities harmed by prohibition. For contrast, consider Illinois, where the Restore, Reinvest, and Renew program (R3) uses 25% of state cannabis tax revenue to provide community grants. 

  • Limited definitions of “impact zones.” These are defined as cities or towns with 120,000 or more residents who rank in the top 40% of cities with the most arrests for possession. Dispensaries will open in these areas first, and some lawmakers have suggested allocating tax revenue from cannabis to impact zone grants.

  • Specifically earmarking tax revenue for law enforcement training. The bill includes language that would use cannabis tax money to train designated police officers as “Drug Recognition Experts,” who will serve to “detect, identify, and apprehend drug-impaired motor vehicle operators.”  

There are other issues. Brandon McKoy, president and chief executive at the New Jersey Policy Perspective, recently wrote that the bill’s proposal to allow just 28 state cultivation licenses would “undermine racial equality and privilege larger corporations at the expense of other applications.”

Gonzalez urged the state to go further in defining qualifications for social equity. “The statute must explicitly outline the requirements for a ‘social equity applicant’ and statutorily mandate the Cannabis Regulatory Commission to create a social equity program to assist these communities in the areas of technical assistance, financial assistance, education, etc.

“In the same vein, the statute must also mandate that a portion of the tax revenue collected be specifically earmarked for the funding of equity programming within the Office of Minorities, Disabled Veterans and Womens Cannabis Development,” she added.

“New Jersey lawmakers have shown they have not really looked at the failures and shortfalls of other states’ attempts to provide reconciliation and equity to those harmed by the war on drugs,” said Tauhid Chappell, executive board member at the Philadelphia Association of Black Journalists and founder of the CannAtlantic cannabis conference.

Chappell also pointed out the legislation’s optional Social Equity Excise Fee, a sliding scale in which the fee goes up as the price goes down, an appetizing condition for large MSOs with the corporate cash reserves to absorb these taxes. 

What happens next?

The situation is still developing. According to NBC Philadelphia, New Jersey’s State Assembly and Senate both canceled meetings scheduled for Monday, Nov. 23, that were partially devoted to ironing out these issues. The next scheduled legislative meeting is Dec. 7.

In the meantime, those working to provide fair access to everyone in the state are seeking help. 

“I am asking them [New Jersey residents] once again to use their voice to speak up against the lack of social equity initiatives in the proposed legislation,” said Gonzalez. “There will be additional Senate and Assembly Committee meetings in the upcoming weeks where folks will have the opportunity to provide oral or written testimony.”

“We need a lot of help and support here,” agreed Chappell. “The window is limited.” He encouraged residents in existing recreational cannabis markets to provide testimony to help lawmakers in New Jersey avoid making the same social equity mistakes made in their state.

“This is not the time to kick back and wait for legalization to come,” advised Gonzalez. “This is the time to get louder with our demands to ensure legalization is equitable. … I highly recommend reviewing the video of the Assembly Committee meeting that took place on November 9th available on the state legislative website. It’s time we all step into the arena.

Published at Wed, 25 Nov 2020 16:00:00 +0000

Novamind Closes Oversubscribed CAD$10 Million Private Placement

Novamind Closes Oversubscribed CAD$10 Million Private Placement

Anticipates trading on CSE under ticker symbol “NM” upon completion of RTO.

TORONTO, ON / ACCESSWIRE / November 23, 2020 /Hinterland Metals Inc. (”Hinterland”) and Novamind Ventures Inc. (”Novamind” or the ”Company”), a leading mental health and wellness company specialized in psychedelic-assisted psychotherapy, today announced that Novamind has closed an oversubscribed private placement of subscription receipts (the ”Financing”), raising aggregate gross proceeds of CAD$10.0 million, twice the original CAD$5.0 million target. With this latest round, Novamind has raised a total of CAD$15.3 million since its inception in 2019.

“The overwhelming support from new and existing shareholders and the interest we received from institutional and retail investors are a testament to the strength of our team, our business model and our opportunities for growth,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “The close of this $10 million round and our anticipated CSE listing are important milestones that will enable us to execute our business plan from a position of strength. Novamind is well capitalized to grow its network of outpatient mental health clinics and clinical research sites, both organically and through acquisitions, with the goal of expanding patient access to alternative mental health treatments, including psychedelic-assisted psychotherapy.”

Novamind’s acquisition and investment strategy began in 2019 with its investment in the Synthesis Institute, a renowned legal psilocybin retreat in the Netherlands. Novamind later announced the acquisition of Utah-based Cedar Psychiatry LLC, which has administered over 3,000 ketamine-assisted psychotherapy treatments since 2016 and is widely recognized as a leader in psychedelic-assisted psychotherapy. In the same transaction, Novamind also acquired Cedar Clinical Research LLC, a dedicated clinical research organization (CRO) with a track record for leading clinical trials and research studies for psychedelic medicines.

On November 17th, 2020, Novamind and Hinterland announced the completion of a definitive amalgamation agreement, pursuant to which Novamind will complete a reverse takeover transaction (the ”Transaction”) with Hinterland with the combined company to be named Novamind Inc. (the ”Resulting Issuer”). The parties expect the Resulting Issuer to begin trading on the Canadian Securities Exchange (the ”CSE”) under the ticker symbol “NM” upon completion of the Transaction, which remains subject to customary conditions, including shareholder approval and the approval of the CSE.

In connection with the Financing, Novamind issued 10,000,000 subscription receipts (”Subscription Receipts”) at a price of CAD$1.00 per Subscription Receipt. Each Subscription Receipt will entitle the holder to receive one common share of the Resulting Issuer. The gross proceeds of the Financing are held in escrow with an escrow agent pending the satisfaction or waiver of all conditions to the completion of the Transaction and conditional listing approval of the CSE.

About Novamind
Founded in 2019, Novamind is building a global network of infrastructure to serve the regulated psychedelics industry. With our wholly-owned subsidiaries, Cedar Psychiatry and Cedar Clinical Research, Novamind is dedicated to providing access to safe and legal psychedelic experiences, while advancing research for psychedelic medicine.

For more information visit

Contact Information
Yaron Conforti, CEO and Director
T: +1 (647) 953 9512

KCSA Strategic Communications

None of the securities issued pursuant to the Financing have been or will be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and any securities issued pursuant to the Financing are anticipated to be issued in reliance upon available exemptions from such registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Completion of the Transaction is subject to a number of conditions. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the Listing Statement (or other disclosure documents to be prepared by the Company or Hinterland) to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the company should be considered highly speculative.

The CSE has not in any way passed upon the merits of the Transaction and have neither approved nor disapproved the contents of this press release. Approval of the CSE for the listing of the common shares of the Resulting Issuer will be subject to, among other things, the Resulting Issuer satisfying the listing requirements of the CSE. There can be no assurance that the approval of the CSE regarding such listing will be obtained.

All information contained in this news release with respect to Novamind and Hinterland was supplied by the parties, respectively, for inclusion herein, and each parties’ directors and officers have relied on each other for any information concerning such party.

Forward-Looking Statements

This news release contains forward-looking statements relating to the timing and completion of the Transaction, the Financing, the listing of the Resulting Issuer on the CSE and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Hinterland, Novamind, and the Resulting Issuer include the failure to satisfy the conditions to completion of the Transaction set forth above and other risks detailed from time to time in the filings made by Hinterland, Novamind and the Resulting Issuer under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Hinterland, Novamind and the Resulting Issuer. As a result, Hinterland, Novamind and the Resulting Issuer cannot guarantee that the Transaction will be completed on the terms and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Hinterland, Novamind and the Resulting Issuer will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Published at Mon, 23 Nov 2020 17:28:10 +0000

High-Potency, Plant-Based Wellness: Dosecann Introduces Cannabis Capsules With Omega-Rich Ahiflower® Oil, A Truly Differentiated Product for the Wellness Consumer

High-Potency, Plant-Based Wellness: Dosecann Introduces Cannabis Capsules With Omega-Rich Ahiflower® Oil, A Truly Differentiated Product for the Wellness Consumer

Today Dosecann, a proprietary in-house brand owned by Auxly Cannabis Group Inc. (TSXV.XLY), announces the launch of Dosecann Capsules, a new, high-quality, precision-dosed cannabis product that combines high-potency, broad-spectrum cannabinoids with omega-rich Ahiflower® oil. Ahiflower oil is a sustainable, plant-based source of the complete and balanced essential omegas the body needs.

Dosecann CBD+Ahiflower Oil Capsules are available now at licensed cannabis retailers across Canada, and also available to patients at Medical Cannabis by Shoppers Drug Mart. In coming weeks, Dosecann will introduce 1:4 (THC:CBD) and THC-based formulations, also using Ahiflower oil.

Dosecann Capsules were developed by a team of scientists and researchers at the state-of-the-art laboratory at the Dosecann facility in Charlottetown, PEI, under the direction of Dr. Bob Chapman, Dosecann’s Chief Science Officer.

“Our innovation team has thoroughly researched and rigorously tested Dosecann Capsules to ensure they are consistent with our guiding principles of quality, safety and efficacy,” said Dr. Bob Chapman, Chief Science Officer, Dosecann. “Balanced, omega-rich Ahiflower oil has proven to be an ideal carrier oil for Dosecann’s refined cannabis resins, which feature the full range of cannabinoids, terpenes, flavonoids and other phytonutrients found in the cannabis plant. The resulting capsule formulations offer all the natural qualities of the cannabis and Ahiflower plants in a convenient capsule format that wellness consumers are sure to love.”

“Dosecann Capsules are a milestone launch, a truly differentiated offering for the wellness consumer segment,” said Brad Canario, Brand Director, Auxly. “Research tells us that consumers are looking for innovative cannabis products in familiar formats that fit their wellness needs and regimens, and we’re thrilled to offer a suite of Dosecann Capsules that combine our consistent and potent cannabinoids with a sustainable and omega-rich carrier oil derived from Ahiflower seeds.”

The cannabinoids in Dosecann Capsules are derived from a whole-plant cannabis resin that preserves the character of the cannabis plant. Through a process of cold-ethanol extraction, this broad-spectrum cannabis resin is further refined and combined with omega-rich Ahiflower oil. Ahiflower oil is exclusively available to Auxly for use in cannabis products through a proprietary, multi-year agreement with Natures Crops International, a vertically integrated grower and manufacturer of plant-based specialty oils. By using Ahiflower oil as a carrier, Dosecann Capsules are immediately differentiated from the vast majority of cannabis oil capsules available in the Canadian marketplace, most of which use MCT. In fact, Dosecann Capsules with Ahiflower are the only capsules that provide consumers with broad-spectrum cannabis and the essential omegas the body needs.

The following list highlights the unique characteristics of Ahiflower oil1, which cannot be attributed to MCT oil:

  • a source of sustainable, traceable, and balanced omega 3-6-9 oil, with a more biologically advanced omega fatty acid composition than any other natural plant-based oil;
  • provides an optimal 4:1 ratio of the essential omega 3-6 fatty acids the body needs;
  • has been shown in clinical trials2 to be safe, well-tolerated, and to increase the concentrations of long-chain omega-3 fatty acids up to four times more effectively than flaxseed oil;
  • unlike flax seed, Ahiflower also contains omega 6 gamma linolenic acid (“GLA”);
  • a sustainably and regeneratively farmed, non-GMO oilseed crop that does not adversely impact ocean ecosystems. Each acre of Ahiflower produces as much omega-rich oil as 320,000 anchovies, frequently used in fish oil.

Click here for more information about the clinical trials conducted with Ahiflower oil.

According to Healthline, essential polyunsaturated omega 3-6-9 oils are clinically associated with a range of health benefits, such as improving cardiovascular health, supporting mental health, fighting inflammation and benefitting skin and hair.

Dosecann CBD Capsules are available in packages of 30, with each capsule containing 25 mg of CBD, 1 mg of THC and 500 mg of Ahiflower oil. The per-capsule omega fatty acid composition is approximately 320 mg of omega 3 (104 mg of stearidonic acid [SDA] + 216 mg of alpha-linolenic acid [ADA]), 85 mg of omega 6 (28 mg GLA + 57 mg of linoleic acid [LA]) and 51 mg of omega 9 oleic fatty acid. In coming weeks, Dosecann will introduce 1:4 Capsules, with each capsule containing 10 mg of CBD and 2.5 mg of THC; and THC Capsules, with each capsule containing 2.5 mg of THC.

The mixture of cannabinoids and Ahiflower oil is then sealed in Lonza’s Licaps® Capsugel® capsules, which are part of Auxly’s multi-year license with Lonza, a global leader in life sciences. Licaps’ patented technology promotes precise, standardized dosing, a longer shelf-life, and rapid digestion. Airtight and leak-proof, Dosecann Capsules are easy to swallow, odorless and tasteless. Click here for more information on the clinical data about Capsugel capsules.

About Dosecann
Dosecann is a world-class developer of innovative cannabis products for the wellness-focused consumer, wholly owned by Auxly Cannabis Group Inc. Proudly processed at Auxly’s 52,000 sq. ft., state-of-the-art facility in Charlottetown, Prince Edward Island, Dosecann products are developed and manufactured on-site by a world-class team of scientists and experts, ensuring high-quality, precision and consistency. Dosecann’s wellness products, available at licensed cannabis retailers across Canada, consist of non-GMO capsules and oils. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science.

Learn more at and stay up to date at Twitter: @Dosecann; Instagram: @dosecann; Facebook: @dosecann.

About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF)
Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

For more information please contact:
Scott Campbell, 647-402-4957,

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes but is not limited to: Dosecann’s execution of its product development and commercialization strategy; consumer preferences; political change, future legislative and regulatory developments involving cannabis, cannabis products and cannabis health products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to whether: there is acceptance and demand for current and future Dosecann products by consumers and provincial purchasers, and general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party sources, the accuracy of which has not been verified by Auxly. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Share - Facebook

Share - Twitter

Published at Mon, 23 Nov 2020 12:39:01 +0000

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform

TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) — PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce it has entered into an exclusive research collaboration agreement with Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for unmet medical needs, to expand Revive’s development plans with psilocybin to treat cancer and to discover novel uses of undisclosed psychedelic compounds.

PharmaTher recently announced the filing of a U.S. provisional patent application outlining the potential novel use of psilocybin to treat cancer, which was discovered by panaceAI™, PharmaTher’s proprietary drug repurposing artificial intelligence platform. The patent application, entitled “Use of Psilocybin in the Treatment of Cancers”, outlines psilocybin’s potential use for Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia.

“We are excited to partner with Revive Therapeutics on our psilocybin cancer program and on panaceAI™ to unlock the potential novel uses of psychedelic compounds in diseases that have sub-optimal or no treatment options,” said Fabio Chianelli, CEO of PharmaTher Inc. “We have been focused on advancing the clinical development of ketamine in the treatment of Parkinson’s disease, while also discovering novel uses of psychedelics using panaceAI™ with the aim to partner these developments. The partnership with Revive allows us to focus on expanding our ketamine programs such as the combination of ketamine with an FDA approved drug and the delivery of ketamine via our proprietary microneedle delivery technology targeting large market opportunities in depression, post-operative and neuropathic pain and disorders of the brain and nervous system.”

The research collaboration with Revive is PharmaTher’s first partnership with panaceAI™ and it validates PharmaTher’s business model in discovering novel uses of psychedelics and partnering these discoveries with life sciences companies seeking to expand their product pipeline with psychedelics.

“Revive continues to be focused on developing novel uses for psilocybin that leverages our proprietary oral thin film delivery technology as a differentiated therapeutic approach,” said Michael Frank, CEO of Revive. “We are excited to advance the development of PharmaTher’s recent discovery in the potential of psilocybin to treat certain cancers and leveraging PharmaTher’s panaceAI™ discovery AI platform to discover new uses of undisclosed psychedelic compounds to expand our psychedelics drug pipeline.”

The collaboration will give Revive the exclusivity to advance the research of psilocybin in the treatment of cancer and leverage PharmaTher’s panaceAI™ psychedelic discovery AI platform to screen, identify and evaluate undisclosed psychedelic compounds directed at pre-specified targets for use with Revive’s drug delivery technology.

About PharmaTher Inc.

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. PharmaTher repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our goal is to advance the commercialization of panaceAI™, our drug repurposing artificial intelligence platform, and our ketamine focused product pipeline in the treatment of Parkinson’s Disease, depression, and pain. Learn more at: and follow us on FacebookTwitter and LinkedIn.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit
For more information, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Inc.
Tel: 1-888-846-3171

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Newscope Capital Corporation’s (the “Company) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to U.S. patent application of psilocybin to treat cancer, psychedelic drug repurposing, drug combinations and discovery, U.S. Food and Drug Administration (“FDA”) approval, panaceAI™, psilocybin and ketamine programs towards human clinical studies under the FDA regulatory pathway and product developments. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on the Company’s profile at

Published at Fri, 20 Nov 2020 18:22:03 +0000

2 Canadian Marijuana Stocks With Future Potential

2 Canadian Marijuana Stocks With Future Potential

2 Canadian Marijuana Stocks With Future Potential | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Sun, 22 Nov 2020 14:33:25 +0000

Whats The Deal With These Marijuana Stocks?

Whats The Deal With These Marijuana Stocks?

Whats The Deal With These Marijuana Stocks? | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Sun, 22 Nov 2020 15:51:29 +0000

Virginia Governor Plans Adult-Use Legalization Bill, Cannabis Legislation Clears Mexico Senate: Week in Review

Virginia Governor Plans Adult-Use Legalization Bill, Cannabis Legislation Clears Mexico Senate: Week in Review

Liberty Health Sciences, a vertically integrated medical marijuana company with operations in Florida, announced in a Nov. 19 press release that it has reached an agreement to settle a class-action suit. The “memorandum of understanding [is] regarding settlement of the securities class action that was commenced against it in the United States in 2019,” the release states.

The settlement figure is $1.8 million US, according to the release, which states: “The settlement is made without any admission or finding of liability and is subject to court approval. There is no assurance that the settlement agreement will receive court approval.”

An attorney representing Liberty wrote in a letter to the judge, overseeing the case in the U.S. District Court for New York’s Southern District, that “Plaintiffs anticipate filing a motion for preliminary settlement approval by January 8, 2021.”

RELATED: How to Raise Capital Without Running Afoul of the SEC

Investors alleged in their January 2019 complaint that Liberty violated securities law. They claimed that Liberty, headquartered in Toronto, Ontario, Canada, “has had longstanding ties” with Aphria, another Canadian cannabis company. Of the “Class Period” between June 28, 2018, and Dec. 3, 2018, the complaint states:

“Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Liberty, in conjunction with Aphria, was involved in a scheme whereby numerous fraudulent acquisitions and transactions were made to provide undue benefits to both companies’ insiders; and (ii) as a result, Liberty’s public statements were materially false and misleading at all relevant times.”

Aphria announced that it sold off its Liberty stake in September 2018, according to the complaint. Then, Quintessential Capital Management and Hindenburg Research published the report “Aphria: A Shell Game with a Cannabis Business on the Side,” alleging a scheme by Aphria to acquire shell companies and sell them off at, as the legal complaint states, “artificially inflated prices.”

“On this news, Liberty’s stock fell $0.36, or nearly 34%, over the next two trading days to close at $0.70 on December 4, 2018,” the complaint stated.

Numerous investors joined the suit against Liberty, according to the complaint. “The members of the Class are so numerous that joinder of all members is impracticable,” it reads.

Proceeding court filings, including amended complaints from Liberty’s attorneys, continued to set forth these allegations and highlight the large numbers of people who allegedly lost money in 2018 because of this “scheme.”

Liberty has dispensary and delivery operations across Florida and also cultivates and processes cannabis, according to its website and the legal complaint. Liberty plans to expand its manufacturing and processing facility, located on a 387-acre parcel of land in Florida, to 490,000 square feet of cultivation space, according to a press release.

Published at Sat, 21 Nov 2020 13:00:00 +0000

Do These Marijuana Stocks Have Good Entry Levels?

Do These Marijuana Stocks Have Good Entry Levels?

Do These Marijuana Stocks Have Good Entry Levels? | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Sat, 21 Nov 2020 21:58:28 +0000

Icanic Brands Has Struck “Ganja Gold” In The California Cannabis Market

Icanic Brands Has Struck “Ganja Gold” In The California Cannabis Market

Icanic Brands Company, Inc. (CSE: ICAN, OTCQB: ICNAF) is a multi-state brand operator that is focused on the cannabis opportunity in California and Nevada. The company is executing on a strategy to become a vertically integrated business in California and owns a portfolio of well-known cannabis brands.

The management team has a proven track record of execution in the cannabis sector and we are favorable on the direction that they have brought the business. From selling branded products to providing white label services, Icanic Brands represents a multi-faceted growth story and is an opportunity that we are following.

Last week, Icanic Brands reported that its wholly owned subsidiary, Ganja Gold, has been recognized by LeafLink as the fastest growing pre-rolls in the nation. by analyzing the orders between 1,700+ cannabis brands and 5,500+ retailers, LeafLink created the LeafLink List. The platform is live in 26 territories across North America and we are favorable on the amount of data that it gathers to determine rankings.

LeafLink’s fastest-growing categories represent the most popular brands and products on the platform in 2020 and we are favorable on the performance of Ganja Gold. The ranking serves as a testament to the strength of Icanic Brands’ product line and we will monitor how it continues to support the growth of the business.

A Differentiated Growth Story

From a intellectual property (IP) standpoint, the management team has been focused on protecting the brand. By focusing on protecting the brand, the company will be able to continue to charge a premium for the product line which should have a positive impact on margins.

Another way the business has been able to differentiate itself is through the use of state-of-the-art technology. By focusing on technology, the company has been able to reduce headcount and this is an important aspect of the story from a margin standpoint.

By focusing on the use of state-of-the-art technology, Icanic Brands’ has been able to grow the white label side of the business and we are bullish on this. Ganja Gold is considered to be a leading brand of infused pre-rolls and we are favorable the amount of brand awareness that it has. Over the next year, we expect the brand to continue to take market share and will monitor how the management team is able to capitalize on the pre-roll market.

We believe the management team has put a major emphasis on cutting costs and ramping revenues. During the last quarter, the stock has been a major out performer and this is a trend that caught our attention.

If you are interested in learning more about Icanic Brands, please send an email to with the subject “Icanic Brands” to be added to our distribution list.


Share - Facebook

Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Thu, 19 Nov 2020 17:35:42 +0000